Sandoz Group AG (SDZ) - Total Assets
Based on the latest financial reports, Sandoz Group AG (SDZ) holds total assets worth CHF22.86 Billion CHF (≈ $28.90 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sandoz Group AG - Total Assets Trend (2020–2025)
This chart illustrates how Sandoz Group AG's total assets have evolved over time, based on quarterly financial data. Also see market cap of Sandoz Group AG for the company's overall valuation and market capitalisation.
Sandoz Group AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Sandoz Group AG's total assets of CHF22.86 Billion consist of 37.1% current assets and 62.9% non-current assets. Review Sandoz Group AG debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF1.74 Billion | 7.9% |
| Accounts Receivable | CHF2.77 Billion | 12.6% |
| Inventory | CHF2.85 Billion | 12.9% |
| Property, Plant & Equipment | CHF2.78 Billion | 12.6% |
| Intangible Assets | CHF1.87 Billion | 8.5% |
| Goodwill | CHF8.01 Billion | 36.4% |
Asset Composition Trend (2020–2025)
This chart illustrates how Sandoz Group AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sandoz Group AG share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sandoz Group AG's current assets represent 37.1% of total assets in 2025, an increase from 31.4% in 2020.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2025, up from 0.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, unchanged from 44.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 36.4% of total assets.
Sandoz Group AG Competitors by Total Assets
Key competitors of Sandoz Group AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.73 Billion |
Sandoz Group AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.05 | 1.29 | 0.64 |
| Quick Ratio | 0.72 | 0.82 | 0.39 |
| Cash Ratio | 0.00 | 0.21 | 0.00 |
| Working Capital | CHF448.21 Million | CHF1.90 Billion | CHF-2.83 Billion |
Sandoz Group AG - Advanced Valuation Insights
This section examines the relationship between Sandoz Group AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.03 |
| Latest Market Cap to Assets Ratio | 1.30 |
| Asset Growth Rate (YoY) | 10.7% |
| Total Assets | CHF22.03 Billion |
| Market Capitalization | $28.58 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Sandoz Group AG's assets above their book value (1.30x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Sandoz Group AG's assets grew by 10.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sandoz Group AG (2020–2025)
The table below shows the annual total assets of Sandoz Group AG from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF22.03 Billion ≈ $27.85 Billion |
+10.67% |
| 2024-12-31 | CHF19.91 Billion ≈ $25.17 Billion |
+2.45% |
| 2023-12-31 | CHF19.43 Billion ≈ $24.56 Billion |
+19429900.00% |
| 2022-12-31 | CHF100.00K ≈ $126.43K |
-100.00% |
| 2021-12-31 | CHF15.98 Billion ≈ $20.21 Billion |
+0.76% |
| 2020-12-31 | CHF15.86 Billion ≈ $20.06 Billion |
-- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more